Cardioxyl Pharmaceuticals

Cardioxyl Pharmaceuticals is a privately-held, clinical-stage biopharmaceutical company developing treatments for cardiovascular diseases, focusing on the discovery, development, and commercialization of novel technologies in therapeutic areas where current treatments are non-existent, ineffective, or inadequate. Cardioxyl has developed industry-leading expertise in the chemistry, biology, and clinical applications of nitroxyl technology. The company’s core nitroxyl platform has generated several preclinical and clinical candidates, including its lead compound CXL-1020, which is currently in clinical development for acute decompensated heart failure, the most common cause of hospitalization for patients over 65.